Proton therapy in pancreatic cancer

Pancreatic cancer, sometimes referred to as the "king of cancer," is one of the most malignant tumors of the digestive system. Its incidence and mortality rates have been rising in both developed and developing countries. The 5-year survival rate after surgical resection — the primary treatment — remains below 10%, the lowest among all gastrointestinal malignancies. For patients who cannot undergo surgery, the prognosis is even grimmer, with most dying within six months of diagnosis.

For patients who are not surgical candidates, concurrent chemoradiation or chemotherapy remains the main course of treatment. However, the pancreas sits close to critical organs — including the gastrointestinal tract, kidneys, and spine — which cannot tolerate high doses of radiation. This forces traditional radiotherapy to operate at lower doses, limiting its effectiveness while still causing significant side effects that many patients struggle to endure.

Proton radiation therapy has attracted growing attention for its ability to concentrate radiation directly at the tumor site while sparing surrounding healthy tissue. Unlike traditional radiotherapy, proton therapy forms a high-dose zone precisely within the tumor — often described as "targeted blasting" — while exposing nearby organs to significantly less radiation. This allows for a higher tumor control rate with fewer early and late side effects to the gastrointestinal tract, liver, kidneys, and spinal cord.

A documented case illustrates this well: a 51-year-old male patient with inoperable pancreatic adenocarcinoma, whose tumor had infiltrated the mesenteric artery and was located next to the abdominal aorta, underwent proton radiation therapy. At a three-year follow-up, his ascites had disappeared, his general condition was good, and the tumor was significantly reduced and effectively controlled — with no obvious adverse reactions.

Proton therapy is not limited to pancreatic cancer. It has demonstrated strong results across a range of cancers including liver, lung, prostate, breast, and ovarian cancer, as well as nasopharyngeal cancer and eye tumors. It is particularly well-suited for pediatric cancers, where minimizing radiation exposure to developing tissues is critical. Proton therapy can effectively improve survival and quality of life in children while protecting their growth and development from the harmful effects of conventional radiation.